Somewhere between a dawn patrol and a slow Tuesday, a quiet thing happened in Miami. The most studied psychedelic of our lifetime got its biggest, most boring, most bulletproof data yet — and that is exactly why it matters. No glow, no guru. Just a thousand people who had run out of options.
What landed at ASCP
At the 2026 American Society of Clinical Psychopharmacology meeting in late May, Compass Pathways laid out late-breaking poster data from two Phase 3 trials of COMP360, a synthetic form of psilocybin, for treatment-resistant depression. COMP005 pitted a single 25 mg dose against placebo and tracked people for 26 weeks. COMP006 compared fixed doses — 1, 10, or 25 mg — head to head. Across the program, more than 1,000 patients were randomized at sites in the United States and Europe, the kind of scale that has been missing from psychedelic science for decades.
The numbers held. Both trials hit their primary endpoint at six weeks on the MADRS depression scale, with results the researchers called highly statistically and clinically significant. These were not easy cases. The entry bar required at least eight weeks of documented antidepressant failure, the average current episode had dragged on more than three years, and only about 5% of participants had ever touched a psychedelic before. That last detail quietly kills the oldest knock on this research — that the trials just recruit true believers who can tell they got the real thing. Two sessions generally beat one. Some people turned a corner after a single dose, and the separation from placebo held all the way to 26 weeks, which almost nothing does in this population.
Why the un-flashy version is the big one
Here is the part worth sitting with. The field's sharpest voices are not calling this a miracle — they are calling it approvable. Researcher Robin Carhart-Harris described the effect as “modest, but still the required hit.” Johns Hopkins' Sandeep Nayak said he expects an approval, pointing to the low rate of prior psychedelic use, the durability data, and a safety profile with no suicidal-ideation signal in the high-dose arm. Even a data scientist at UCSF who was lukewarm on the magnitude figured the package is probably enough for the FDA. Compass is aiming to start a rolling application by the end of 2026, which could put the first legal, prescribable psilocybin in front of regulators within months, not years.
Sit with the arc. Psilocybin spent half a century as contraband and counterculture shorthand — the thing that got research shut down in the first place. The route back was not a manifesto. It was a stack of paperwork: documented treatment failure as a requirement, a hard cap on prior use, durability tracked for half a year, and a chief medical officer repeating to anyone who would listen that they did not cut a single corner. With a federal push to fast-track breakthrough psychedelics now in the mix, the bottleneck is no longer belief. It is process. The rebellion, this time, is the rigor.
That is the part that fits how we see it. The people who actually know a thing do not need to shout about it — they put in the reps and let the work answer. A mushroom that grew in a cow field is sitting in a federal inbox because somebody ran the dull trial a thousand times and wrote down every number. Pay attention to the quiet ones. If you KNOW, you NOE.
Sources:
- Psychiatric Times — Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting
- Psychedelic Alpha — After the Readout: How the Field Is Interpreting Compass' Phase 3 Psilocybin Data
- BioPharma Dive — Compass, with Phase 3 hits, ready to take psilocybin to the FDA
This post is editorial reporting. Nothing here is medical advice. Psychedelic compounds are controlled substances in most jurisdictions. If you're struggling, talk to a licensed professional.